EcoDrugPlus

Proteasome 26s Subunit, Non-Atpase 1

Ensembl ID : ENSDCDG00000035814
Gene Symbol: PSMD1
3 Cross references
215 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 11

Ensembl ID : ENSDCDG00000017299
Gene Symbol: PSMD11
3 Cross references
270 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 12

Ensembl ID : ENSDCDG00000034057
Gene Symbol: PSMD12
3 Cross references
222 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 13

Ensembl ID : ENSDCDG00000030543
Gene Symbol: PSMD13
3 Cross references
219 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 14

Ensembl ID : ENSDCDG00000002481
Gene Symbol: PSMD14
3 Cross references
215 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 2

Ensembl ID : ENSDCDG00000021982
Gene Symbol: PSMD2
3 Cross references
224 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 6

Ensembl ID : ENSDCDG00000017348
Gene Symbol: PSMD6
3 Cross references
213 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 7

Ensembl ID : ENSDCDG00000028484
Gene Symbol: PSMD7
3 Cross references
235 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 8

Ensembl ID : ENSDCDG00000029030
Gene Symbol: PSMD8
3 Cross references
213 Possible Orthologues:

Proteasome Subunit Alpha Type-6

Ensembl ID : ENSDCDG00000004538
Gene Symbol: LOC114803238
3 Cross references
261 Possible Orthologues:

Proteasome Subunit Alpha Type-7

Ensembl ID : ENSDCDG00000027165
Gene Symbol: LOC114788293
3 Cross references
184 Possible Orthologues:

Proteasome Subunit Beta 11

Ensembl ID : ENSDCDG00000020746
Gene Symbol: PSMB11
1 Cross references
105 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).